2. Anti-infection Cell Cycle/DNA Damage Immunology/Inflammation Apoptosis
  3. Bacterial DNA/RNA Synthesis Nuclear Factor of activated T Cells (NFAT) Apoptosis
  4. Usnic acid

Usnic acid is a secondary metabolite of lichens with a unique dibenzofuran skeleton. Usnic acid inhibits DNA/RNA synthesis and has antibacterial activity. Usnic acid induces cell cycle arrest and apoptosis and has anticancer activity. Usnic acid inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1. Usnic acid has antioxidant and anti-inflammatory activities by inhibiting lipid peroxidation and myeloperoxidase.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Usnic acid

Usnic acid 構造式

CAS 番号 : 125-46-2

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
100 mg $30 在庫あり
500 mg $50 在庫あり
1 g   お問い合わせ  
5 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Other Forms of Usnic acid:

Usnic acid 関連抗体

Top Publications Citing Use of Products

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Usnic acid is a secondary metabolite of lichens with a unique dibenzofuran skeleton. Usnic acid inhibits DNA/RNA synthesis and has antibacterial activity. Usnic acid induces cell cycle arrest and apoptosis and has anticancer activity. Usnic acid inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1. Usnic acid has antioxidant and anti-inflammatory activities by inhibiting lipid peroxidation and myeloperoxidase[1][2][3][4].

Cellular Effect
Cell Line Type Value Description References
HeLa IC50
10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
>10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
>10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
>10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
HeLa IC50
10 3
Compound: (+)-1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
>10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
>10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
>10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
MCF7 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (+)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 31282672]
PC-3 IC50
> 10 3
Compound: (-)-1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31282672]
体外実験

Usnic acid (0-40 μg/mL, 0-150 min) inhibits the growth of B. subtilis, S. aureus and V. harveyi[1].
Usnic acid (0.5/1 μg/mL, 15-150 min) inhibits the incorporation rate of DNA, RNA and protein synthesis macromolecular precursors thymidine, uridine and leucine in B. subtilis and S. aureus[1].
Usnic acid (25-100 μM, 24-48 h) inhibits the viability and clonogenicity of A549 cells. It also induces G0/G1 cell cycle arrest, mitochondrial membrane depolarization and apoptosis of A549 cells[2].
Usnic acid (0.3-3 μM, 4 d) inhibits the differentiation of bone marrow-derived macrophages (BMM) into mature osteoclasts in a dose-dependent manner[4].
Usnic acid (3 μM, 0-3 d) inhibits the transcriptional and translational expression of RANKL on NFATc1 in BMMs[4].
Usnic acid (3 μM, 5-30 min) inhibits RANKL-induced activities of MAP kinases p38, ERK and JNK in BMMs[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Usnic acid 関連抗体

Cell Viability Assay[2]

Cell Line: A549 cells
Concentration: 25, 50, 100 μM
Incubation Time: 24/48 h
Result: Inhibited cell proliferation (35-48%/59-72%).

Cell Proliferation Assay[2]

Cell Line: A549 cells
Concentration: 1, 5, 10 μM
Incubation Time: 7 days
Result: Inhibited cell colony formation (8, 23, 85%).

Cell Cycle Analysis[2]

Cell Line: A549 cells
Concentration: 25, 50, 100 μM
Incubation Time: 24/48 h
Result: Induced cell cycle arrest at G0/G1 (77%, 81% and 80%; 87%, 85%, and 82%).
Down-regulated CDK4, CDK-6 and cyclin D1 protein levels.
Up-regulated p21/Cip1 protein and cleaved-PARP levels.

Apoptosis Analysis[2]

Cell Line: A549 cells
Concentration: 25, 50, 100 μM
Incubation Time: 48 h
Result: Increased the number of apoptotic cells (6%, 10% and 11%).

RT-PCR[4]

Cell Line: BMMs
Concentration: Usnic acid (3 µM) for 1 h prior to RANKL (10 ng/mL) and M-CSF (30 ng/mL) stimulation
Incubation Time: 0, 1, 2, 3 d
Result: Down-regulated the gene expression levels of TRAP, DC-STAMP, and cathepsin K.

Western Blot Analysis[4]

Cell Line: BMMs
Concentration: Usnic acid (3 µM) for 1 h prior to RANKL (10 ng/mL) stimulation
Incubation Time: 5, 15, 30 min
Result: Down-regulated the protein expression levels of p38, ERK and JNK.
体内実験

Usnic acid (25-200 mg/kg, p.o., once) can inhibit Indomethacin (HY-14397)-induced gastric injury in rats (80.2-96.4%)[3].
Usnic acid (1 μg/g, i.p., every day for up to 8 days) inhibited osteoclastic bone resorption in the lipopolysaccharide (LPS) bone erosion model [4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Indomethacin-induced gastric damage model (male, Albino-Wistar rats, weighing 180-190 g; Indomethacin 25 mg/kg body weight orally.)[3]
Dosage: 25, 50, 100 and 200 mg/kg
Administration: Oral gavage (p.o.), once
Result: Reduced gastric damage in rats (80.2-96.4%).
Increased SOD, GPx, GSH and cNOS levels.
Reduced CAT, GR, LPO, iNOS and MPx levels.
Animal Model: LPS-induced mouse bone erosion model (five-week-old male ICR mice, 5 µg/µL LPS was injected intraperitoneally on days 1 and 4)[4]
Dosage: 1 μg/g
Administration: Intraperitoneal injection (i.p.), every day for up to 8 days
Result: Increased BMD and BV/TV.
Reduced BS/TV and Tb.Sp.
分子量

344.32

分子式

C18H16O7
CAS 番号
Appearance

Solid

Color

White to yellow

SMILES

O=C(C1(C)C(OC2=C(C(C)=O)C(O)=C(C)C(O)=C12)=C3)C(C(C)=O)C3=O
Structure Classification
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度
体外: 

DMSO : 3.33 mg/mL (9.67 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9043 mL 14.5214 mL 29.0428 mL
5 mM 0.5809 mL 2.9043 mL 5.8085 mL
10 mM --- --- ---
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 2 mg/mL (5.81 mM); Suspended solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  0.5% CMC-Na/saline water

    Solubility: 2 mg/mL (5.81 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
純度とドキュメンテーション

純度: 98.90%

COA (259 KB) HNMR (251 KB) RP-HPLC (261 KB) LCMS (97 KB)

取扱説明書 (2659 KB)
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.9043 mL 14.5214 mL 29.0428 mL 72.6069 mL
5 mM 0.5809 mL 2.9043 mL 5.8086 mL 14.5214 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Usnic acid Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Usnic acid125-46-2BacterialDNA/RNA SynthesisNuclear Factor of activated T Cells (NFAT)ApoptosisAntibacterialAnticancerB. subtilisS. aureusA549 cellsBMMsIndomethacin-induced gastric damage modelLPS-induced mouse bone erosion modelInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Usnic acid
製品番号:
HY-N0656
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.